Several other domestically developed third-generation EGFR-TKIs such as rezivertinib (BPI7711), limertinib (ASK120067), befotertinib (D-0316), and oritinib (SH-1028) have also shown favorable efficacy and safety among patients with NSCLC showing EGFR T790M mutations.40, 41, 42, 43, 44. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.